Global Immunotherapy for Neuroblastoma Market Growth (Status and Outlook) 2025-2031
The global Immunotherapy for Neuroblastoma market size is predicted to grow from US$ 50.9 million in 2025 to US$ 67.4 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
United States market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immunotherapy for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Immunotherapy for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy for Neuroblastoma sales in 2024, providing a comprehensive analysis by region and market sector of projected Immunotherapy for Neuroblastoma sales for 2025 through 2031. With Immunotherapy for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immunotherapy for Neuroblastoma industry.
This Insight Report provides a comprehensive analysis of the global Immunotherapy for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immunotherapy for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immunotherapy for Neuroblastoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy for Neuroblastoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy for Neuroblastoma.
This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy for Neuroblastoma market by product type, application, key players and key regions and countries.
Segmentation by Type:
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
United States market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immunotherapy for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Immunotherapy for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy for Neuroblastoma sales in 2024, providing a comprehensive analysis by region and market sector of projected Immunotherapy for Neuroblastoma sales for 2025 through 2031. With Immunotherapy for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immunotherapy for Neuroblastoma industry.
This Insight Report provides a comprehensive analysis of the global Immunotherapy for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immunotherapy for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immunotherapy for Neuroblastoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy for Neuroblastoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy for Neuroblastoma.
This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy for Neuroblastoma market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Dinutuximab
- Naxitamab
- Other
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immunotherapy for Neuroblastoma Market Size (2020-2031)
2.1.2 Immunotherapy for Neuroblastoma Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Immunotherapy for Neuroblastoma by Country/Region (2020, 2024 & 2031)
2.2 Immunotherapy for Neuroblastoma Segment by Type
2.2.1 Dinutuximab
2.2.2 Naxitamab
2.2.3 Other
2.3 Immunotherapy for Neuroblastoma Market Size by Type
2.3.1 Immunotherapy for Neuroblastoma Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
2.4 Immunotherapy for Neuroblastoma Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Immunotherapy for Neuroblastoma Market Size by Application
2.5.1 Immunotherapy for Neuroblastoma Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
3 IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET SIZE BY PLAYER
3.1 Immunotherapy for Neuroblastoma Market Size Market Share by Player
3.1.1 Global Immunotherapy for Neuroblastoma Revenue by Player (2020-2025)
3.1.2 Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2020-2025)
3.2 Global Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNOTHERAPY FOR NEUROBLASTOMA BY REGION
4.1 Immunotherapy for Neuroblastoma Market Size by Region (2020-2025)
4.2 Global Immunotherapy for Neuroblastoma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
4.4 APAC Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
4.5 Europe Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
4.6 Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)
5.2 Americas Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
5.3 Americas Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunotherapy for Neuroblastoma Market Size by Region (2020-2025)
6.2 APAC Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
6.3 APAC Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)
7.2 Europe Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
7.3 Europe Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immunotherapy for Neuroblastoma by Region (2020-2025)
8.2 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
8.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET FORECAST
10.1 Global Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.1.1 Global Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.1.2 Americas Immunotherapy for Neuroblastoma Forecast
10.1.3 APAC Immunotherapy for Neuroblastoma Forecast
10.1.4 Europe Immunotherapy for Neuroblastoma Forecast
10.1.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast
10.2 Americas Immunotherapy for Neuroblastoma Forecast by Country (2026-2031)
10.2.1 United States Market Immunotherapy for Neuroblastoma Forecast
10.2.2 Canada Market Immunotherapy for Neuroblastoma Forecast
10.2.3 Mexico Market Immunotherapy for Neuroblastoma Forecast
10.2.4 Brazil Market Immunotherapy for Neuroblastoma Forecast
10.3 APAC Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.3.1 China Immunotherapy for Neuroblastoma Market Forecast
10.3.2 Japan Market Immunotherapy for Neuroblastoma Forecast
10.3.3 Korea Market Immunotherapy for Neuroblastoma Forecast
10.3.4 Southeast Asia Market Immunotherapy for Neuroblastoma Forecast
10.3.5 India Market Immunotherapy for Neuroblastoma Forecast
10.3.6 Australia Market Immunotherapy for Neuroblastoma Forecast
10.4 Europe Immunotherapy for Neuroblastoma Forecast by Country (2026-2031)
10.4.1 Germany Market Immunotherapy for Neuroblastoma Forecast
10.4.2 France Market Immunotherapy for Neuroblastoma Forecast
10.4.3 UK Market Immunotherapy for Neuroblastoma Forecast
10.4.4 Italy Market Immunotherapy for Neuroblastoma Forecast
10.4.5 Russia Market Immunotherapy for Neuroblastoma Forecast
10.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.5.1 Egypt Market Immunotherapy for Neuroblastoma Forecast
10.5.2 South Africa Market Immunotherapy for Neuroblastoma Forecast
10.5.3 Israel Market Immunotherapy for Neuroblastoma Forecast
10.5.4 Turkey Market Immunotherapy for Neuroblastoma Forecast
10.6 Global Immunotherapy for Neuroblastoma Forecast by Type (2026-2031)
10.7 Global Immunotherapy for Neuroblastoma Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Immunotherapy for Neuroblastoma Forecast
11 KEY PLAYERS ANALYSIS
11.1 United Therapeutics
11.1.1 United Therapeutics Company Information
11.1.2 United Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.1.3 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 United Therapeutics Main Business Overview
11.1.5 United Therapeutics Latest Developments
11.2 Y-mAbs Therapeutics
11.2.1 Y-mAbs Therapeutics Company Information
11.2.2 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Y-mAbs Therapeutics Main Business Overview
11.2.5 Y-mAbs Therapeutics Latest Developments
11.3 EUSA Pharma
11.3.1 EUSA Pharma Company Information
11.3.2 EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
11.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 EUSA Pharma Main Business Overview
11.3.5 EUSA Pharma Latest Developments
11.4 ANI Pharmaceuticals
11.4.1 ANI Pharmaceuticals Company Information
11.4.2 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 ANI Pharmaceuticals Main Business Overview
11.4.5 ANI Pharmaceuticals Latest Developments
11.5 Baxter Healthcare
11.5.1 Baxter Healthcare Company Information
11.5.2 Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
11.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Baxter Healthcare Main Business Overview
11.5.5 Baxter Healthcare Latest Developments
11.6 Ingenus Pharmaceuticals
11.6.1 Ingenus Pharmaceuticals Company Information
11.6.2 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Ingenus Pharmaceuticals Main Business Overview
11.6.5 Ingenus Pharmaceuticals Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Immunotherapy for Neuroblastoma Product Offered
11.7.3 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 Hikma Pharmaceuticals
11.8.1 Hikma Pharmaceuticals Company Information
11.8.2 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Hikma Pharmaceuticals Main Business Overview
11.8.5 Hikma Pharmaceuticals Latest Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Information
11.9.2 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Teva Pharmaceuticals Main Business Overview
11.9.5 Teva Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immunotherapy for Neuroblastoma Market Size (2020-2031)
2.1.2 Immunotherapy for Neuroblastoma Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Immunotherapy for Neuroblastoma by Country/Region (2020, 2024 & 2031)
2.2 Immunotherapy for Neuroblastoma Segment by Type
2.2.1 Dinutuximab
2.2.2 Naxitamab
2.2.3 Other
2.3 Immunotherapy for Neuroblastoma Market Size by Type
2.3.1 Immunotherapy for Neuroblastoma Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
2.4 Immunotherapy for Neuroblastoma Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Immunotherapy for Neuroblastoma Market Size by Application
2.5.1 Immunotherapy for Neuroblastoma Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
3 IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET SIZE BY PLAYER
3.1 Immunotherapy for Neuroblastoma Market Size Market Share by Player
3.1.1 Global Immunotherapy for Neuroblastoma Revenue by Player (2020-2025)
3.1.2 Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2020-2025)
3.2 Global Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNOTHERAPY FOR NEUROBLASTOMA BY REGION
4.1 Immunotherapy for Neuroblastoma Market Size by Region (2020-2025)
4.2 Global Immunotherapy for Neuroblastoma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
4.4 APAC Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
4.5 Europe Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
4.6 Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)
5.2 Americas Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
5.3 Americas Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunotherapy for Neuroblastoma Market Size by Region (2020-2025)
6.2 APAC Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
6.3 APAC Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)
7.2 Europe Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
7.3 Europe Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immunotherapy for Neuroblastoma by Region (2020-2025)
8.2 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2020-2025)
8.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET FORECAST
10.1 Global Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.1.1 Global Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.1.2 Americas Immunotherapy for Neuroblastoma Forecast
10.1.3 APAC Immunotherapy for Neuroblastoma Forecast
10.1.4 Europe Immunotherapy for Neuroblastoma Forecast
10.1.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast
10.2 Americas Immunotherapy for Neuroblastoma Forecast by Country (2026-2031)
10.2.1 United States Market Immunotherapy for Neuroblastoma Forecast
10.2.2 Canada Market Immunotherapy for Neuroblastoma Forecast
10.2.3 Mexico Market Immunotherapy for Neuroblastoma Forecast
10.2.4 Brazil Market Immunotherapy for Neuroblastoma Forecast
10.3 APAC Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.3.1 China Immunotherapy for Neuroblastoma Market Forecast
10.3.2 Japan Market Immunotherapy for Neuroblastoma Forecast
10.3.3 Korea Market Immunotherapy for Neuroblastoma Forecast
10.3.4 Southeast Asia Market Immunotherapy for Neuroblastoma Forecast
10.3.5 India Market Immunotherapy for Neuroblastoma Forecast
10.3.6 Australia Market Immunotherapy for Neuroblastoma Forecast
10.4 Europe Immunotherapy for Neuroblastoma Forecast by Country (2026-2031)
10.4.1 Germany Market Immunotherapy for Neuroblastoma Forecast
10.4.2 France Market Immunotherapy for Neuroblastoma Forecast
10.4.3 UK Market Immunotherapy for Neuroblastoma Forecast
10.4.4 Italy Market Immunotherapy for Neuroblastoma Forecast
10.4.5 Russia Market Immunotherapy for Neuroblastoma Forecast
10.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast by Region (2026-2031)
10.5.1 Egypt Market Immunotherapy for Neuroblastoma Forecast
10.5.2 South Africa Market Immunotherapy for Neuroblastoma Forecast
10.5.3 Israel Market Immunotherapy for Neuroblastoma Forecast
10.5.4 Turkey Market Immunotherapy for Neuroblastoma Forecast
10.6 Global Immunotherapy for Neuroblastoma Forecast by Type (2026-2031)
10.7 Global Immunotherapy for Neuroblastoma Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Immunotherapy for Neuroblastoma Forecast
11 KEY PLAYERS ANALYSIS
11.1 United Therapeutics
11.1.1 United Therapeutics Company Information
11.1.2 United Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.1.3 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 United Therapeutics Main Business Overview
11.1.5 United Therapeutics Latest Developments
11.2 Y-mAbs Therapeutics
11.2.1 Y-mAbs Therapeutics Company Information
11.2.2 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Y-mAbs Therapeutics Main Business Overview
11.2.5 Y-mAbs Therapeutics Latest Developments
11.3 EUSA Pharma
11.3.1 EUSA Pharma Company Information
11.3.2 EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
11.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 EUSA Pharma Main Business Overview
11.3.5 EUSA Pharma Latest Developments
11.4 ANI Pharmaceuticals
11.4.1 ANI Pharmaceuticals Company Information
11.4.2 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 ANI Pharmaceuticals Main Business Overview
11.4.5 ANI Pharmaceuticals Latest Developments
11.5 Baxter Healthcare
11.5.1 Baxter Healthcare Company Information
11.5.2 Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
11.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Baxter Healthcare Main Business Overview
11.5.5 Baxter Healthcare Latest Developments
11.6 Ingenus Pharmaceuticals
11.6.1 Ingenus Pharmaceuticals Company Information
11.6.2 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Ingenus Pharmaceuticals Main Business Overview
11.6.5 Ingenus Pharmaceuticals Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Immunotherapy for Neuroblastoma Product Offered
11.7.3 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 Hikma Pharmaceuticals
11.8.1 Hikma Pharmaceuticals Company Information
11.8.2 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Hikma Pharmaceuticals Main Business Overview
11.8.5 Hikma Pharmaceuticals Latest Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Information
11.9.2 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Teva Pharmaceuticals Main Business Overview
11.9.5 Teva Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Immunotherapy for Neuroblastoma Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Immunotherapy for Neuroblastoma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Dinutuximab
Table 4. Major Players of Naxitamab
Table 5. Major Players of Other
Table 6. Immunotherapy for Neuroblastoma Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Table 9. Immunotherapy for Neuroblastoma Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Table 12. Global Immunotherapy for Neuroblastoma Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2020-2025)
Table 14. Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
Table 15. Immunotherapy for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Table 20. Global Immunotherapy for Neuroblastoma Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Immunotherapy for Neuroblastoma Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Country (2020-2025)
Table 24. Americas Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Table 26. Americas Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Table 28. APAC Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Table 30. APAC Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country (2020-2025)
Table 34. Europe Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Immunotherapy for Neuroblastoma
Table 40. Key Market Challenges & Risks of Immunotherapy for Neuroblastoma
Table 41. Key Industry Trends of Immunotherapy for Neuroblastoma
Table 42. Global Immunotherapy for Neuroblastoma Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Immunotherapy for Neuroblastoma Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Immunotherapy for Neuroblastoma Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. United Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 47. United Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 48. United Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. United Therapeutics Main Business
Table 50. United Therapeutics Latest Developments
Table 51. Y-mAbs Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 52. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 53. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. Y-mAbs Therapeutics Main Business
Table 55. Y-mAbs Therapeutics Latest Developments
Table 56. EUSA Pharma Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 57. EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
Table 58. EUSA Pharma Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. EUSA Pharma Main Business
Table 60. EUSA Pharma Latest Developments
Table 61. ANI Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 62. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 63. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. ANI Pharmaceuticals Main Business
Table 65. ANI Pharmaceuticals Latest Developments
Table 66. Baxter Healthcare Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 67. Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
Table 68. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Baxter Healthcare Main Business
Table 70. Baxter Healthcare Latest Developments
Table 71. Ingenus Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 72. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 73. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Ingenus Pharmaceuticals Main Business
Table 75. Ingenus Pharmaceuticals Latest Developments
Table 76. Pfizer Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 77. Pfizer Immunotherapy for Neuroblastoma Product Offered
Table 78. Pfizer Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Pfizer Main Business
Table 80. Pfizer Latest Developments
Table 81. Hikma Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 82. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 83. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. Hikma Pharmaceuticals Main Business
Table 85. Hikma Pharmaceuticals Latest Developments
Table 86. Teva Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 87. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 88. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 89. Teva Pharmaceuticals Main Business
Table 90. Teva Pharmaceuticals Latest Developments
Table 1. Immunotherapy for Neuroblastoma Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Immunotherapy for Neuroblastoma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Dinutuximab
Table 4. Major Players of Naxitamab
Table 5. Major Players of Other
Table 6. Immunotherapy for Neuroblastoma Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Table 9. Immunotherapy for Neuroblastoma Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Table 12. Global Immunotherapy for Neuroblastoma Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2020-2025)
Table 14. Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
Table 15. Immunotherapy for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Table 20. Global Immunotherapy for Neuroblastoma Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Immunotherapy for Neuroblastoma Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Country (2020-2025)
Table 24. Americas Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Table 26. Americas Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Table 28. APAC Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Table 30. APAC Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country (2020-2025)
Table 34. Europe Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Immunotherapy for Neuroblastoma
Table 40. Key Market Challenges & Risks of Immunotherapy for Neuroblastoma
Table 41. Key Industry Trends of Immunotherapy for Neuroblastoma
Table 42. Global Immunotherapy for Neuroblastoma Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Immunotherapy for Neuroblastoma Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Immunotherapy for Neuroblastoma Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. United Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 47. United Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 48. United Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. United Therapeutics Main Business
Table 50. United Therapeutics Latest Developments
Table 51. Y-mAbs Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 52. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 53. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. Y-mAbs Therapeutics Main Business
Table 55. Y-mAbs Therapeutics Latest Developments
Table 56. EUSA Pharma Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 57. EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
Table 58. EUSA Pharma Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. EUSA Pharma Main Business
Table 60. EUSA Pharma Latest Developments
Table 61. ANI Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 62. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 63. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. ANI Pharmaceuticals Main Business
Table 65. ANI Pharmaceuticals Latest Developments
Table 66. Baxter Healthcare Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 67. Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
Table 68. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Baxter Healthcare Main Business
Table 70. Baxter Healthcare Latest Developments
Table 71. Ingenus Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 72. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 73. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Ingenus Pharmaceuticals Main Business
Table 75. Ingenus Pharmaceuticals Latest Developments
Table 76. Pfizer Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 77. Pfizer Immunotherapy for Neuroblastoma Product Offered
Table 78. Pfizer Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Pfizer Main Business
Table 80. Pfizer Latest Developments
Table 81. Hikma Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 82. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 83. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. Hikma Pharmaceuticals Main Business
Table 85. Hikma Pharmaceuticals Latest Developments
Table 86. Teva Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 87. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 88. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 89. Teva Pharmaceuticals Main Business
Table 90. Teva Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Immunotherapy for Neuroblastoma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immunotherapy for Neuroblastoma Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Immunotherapy for Neuroblastoma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2024)
Figure 8. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2024
Figure 10. Immunotherapy for Neuroblastoma in Hospital
Figure 11. Global Immunotherapy for Neuroblastoma Market: Hospital (2020-2025) & ($ millions)
Figure 12. Immunotherapy for Neuroblastoma in Clinic
Figure 13. Global Immunotherapy for Neuroblastoma Market: Clinic (2020-2025) & ($ millions)
Figure 14. Immunotherapy for Neuroblastoma in Other
Figure 15. Global Immunotherapy for Neuroblastoma Market: Other (2020-2025) & ($ millions)
Figure 16. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2024
Figure 17. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player in 2024
Figure 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Figure 19. Americas Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 20. APAC Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 21. Europe Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 23. Americas Immunotherapy for Neuroblastoma Value Market Share by Country in 2024
Figure 24. United States Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region in 2024
Figure 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Figure 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Figure 31. China Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 35. India Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country in 2024
Figure 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Figure 39. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Figure 40. Germany Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 41. France Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 54. APAC Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 55. Europe Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 57. United States Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 58. Canada Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 59. Mexico Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 60. Brazil Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 61. China Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 62. Japan Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 63. Korea Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 65. India Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 66. Australia Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 67. Germany Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 68. France Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 69. UK Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 70. Italy Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 71. Russia Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 72. Egypt Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 73. South Africa Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 74. Israel Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 75. Turkey Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 76. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 1. Immunotherapy for Neuroblastoma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immunotherapy for Neuroblastoma Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Immunotherapy for Neuroblastoma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2024)
Figure 8. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2024
Figure 10. Immunotherapy for Neuroblastoma in Hospital
Figure 11. Global Immunotherapy for Neuroblastoma Market: Hospital (2020-2025) & ($ millions)
Figure 12. Immunotherapy for Neuroblastoma in Clinic
Figure 13. Global Immunotherapy for Neuroblastoma Market: Clinic (2020-2025) & ($ millions)
Figure 14. Immunotherapy for Neuroblastoma in Other
Figure 15. Global Immunotherapy for Neuroblastoma Market: Other (2020-2025) & ($ millions)
Figure 16. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2024
Figure 17. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player in 2024
Figure 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Figure 19. Americas Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 20. APAC Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 21. Europe Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2020-2025 ($ millions)
Figure 23. Americas Immunotherapy for Neuroblastoma Value Market Share by Country in 2024
Figure 24. United States Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region in 2024
Figure 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Figure 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Figure 31. China Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 35. India Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country in 2024
Figure 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Figure 39. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Figure 40. Germany Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 41. France Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Immunotherapy for Neuroblastoma Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 54. APAC Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 55. Europe Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 57. United States Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 58. Canada Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 59. Mexico Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 60. Brazil Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 61. China Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 62. Japan Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 63. Korea Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 65. India Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 66. Australia Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 67. Germany Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 68. France Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 69. UK Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 70. Italy Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 71. Russia Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 72. Egypt Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 73. South Africa Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 74. Israel Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 75. Turkey Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
Figure 76. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Immunotherapy for Neuroblastoma Market Size 2026-2031 ($ millions)
